专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07892740B2 Prognosis and therapy predictive markers and methods of use 有权
标题翻译：预后和治疗预测标记及使用方法
公开(公告)号：US07892740B2
公开(公告)日：2011-02-22
申请号：US12087964
申请日：2007-01-19
申请人： Ralph Weichselbaum , Bernard Roizman , Andy Minn , Nikolai Khodarev , Edwardine Labay
发明人： Ralph Weichselbaum , Bernard Roizman , Andy Minn , Nikolai Khodarev , Edwardine Labay
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , G01N33/57407 , G01N33/57484 , G01N2800/52
摘要： Disclosed is a set of genes differentially expressed in chemotherapy and radiation resistant tumors useful in predicting response to therapy and assessing risk of local-regional failure, survival and metastasis in cancer patients. Also disclosed are methods for characterizing tumors according to gene expression and kits for use in the methods of the invention.
摘要翻译：公开了一组在化学疗法和耐辐射肿瘤中差异表达的基因，可用于预测治疗反应和评估癌症患者局部局部衰竭，存活和转移的风险。还公开了根据基因表达表征肿瘤的方法和用于本发明方法的试剂盒。

2. 发明授权

US08178505B2 Method of predicting and reducing risk of metastasis of breast cancer to lung 有权
标题翻译：预测和降低乳腺癌肺转移风险的方法
公开(公告)号：US08178505B2
公开(公告)日：2012-05-15
申请号：US11813407
申请日：2006-01-05
申请人： Joan Massague , Gaorav P. Gupta , Andy Minn
发明人： Joan Massague , Gaorav P. Gupta , Andy Minn
IPC分类号： A61K48/00 , C07H21/04 , C07H21/02 , C07K14/00
CPC分类号： C12N15/1137 , C12N15/1136 , C12N2310/14 , C12Y114/99001
摘要： A signature for breast cancer tissue derived from a patient is established that is indicative of the virulence and risk of lung metastasis by determining the expression levels to define a sample signature, and comparing this sample signature to a reference signature. The reference signature defines a standard expression level for each gene and a significant change direction, i.e., either overexpressed or underexpressed. A sample signature that differs from the reference signature in the significant change direction for a predetermined number of the genes tested is indicative of a significant risk of lung metastasis. This determination is used to define appropriate treatment and monitoring options for the patient. Risk of metastasis to the lung can be reduced by treatment with a therapeutic combination that either (1) contains a first agent effective to inhibit epiregulin activity and a second agent effective to inhibit activity of a protein selected from the group consisting of MMP1, MMP2 and PTGS2, or (2) contains a therapeutic agent or combination of agents effective to inhibit activity MMP1, MMP2 and PTGS2. Agents that inhibit the CXCL1 pathway also can be used individually or in combination with these combinations.
摘要翻译：通过确定表达水平来确定样品标记，并将该样本标记与参考标记进行比较，建立了从患者衍生的乳腺癌组织的特征，其指示肺转移的毒力和风险。参考标记定义每个基因的标准表达水平和显着改变方向，即过表达或低表达。对于预定数量的所测试的基因，在显着改变方向上与参考标记不同的样本标记指示肺转移的显着风险。该确定用于为患者定义适当的治疗和监测选项。可以通过用（1）含有有效抑制去甲孕腺素活性的第一药剂和有效抑制选自MMP1，MMP2和 PTGS2或（2）含有有效抑制MMP1，MMP2和PTGS2活性的治疗剂或药剂组合。抑制CXCL1途径的药剂也可以单独使用或与这些组合组合使用。

3. 发明申请

US20110200998A1 Prognosis and Therapy Predictive Markers and Methods of Use 审中-公开
标题翻译：预后和治疗预测标记和使用方法
公开(公告)号：US20110200998A1
公开(公告)日：2011-08-18
申请号：US13023331
申请日：2011-02-08
申请人： Ralph Weichselbaum , Bernard Roizman , Andy Minn , Nikolai Khodarev , Edwardine Labay
发明人： Ralph Weichselbaum , Bernard Roizman , Andy Minn , Nikolai Khodarev , Edwardine Labay
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , G01N33/57407 , G01N33/57484 , G01N2800/52
摘要： Disclosed is a set of genes differentially expressed in chemotherapy and radiation resistant tumors useful in predicting response to therapy and assessing risk of local-regional failure, survival and metastasis in cancer patients. Also disclosed are methods for characterizing tumors according to gene expression and kits for use in the methods of the invention.
摘要翻译：公开了一组在化学疗法和耐辐射肿瘤中差异表达的基因，可用于预测治疗反应和评估癌症患者局部局部衰竭，存活和转移的风险。还公开了根据基因表达表征肿瘤的方法和用于本发明方法的试剂盒。

4. 发明申请

US20090011439A1 Prognosis and Therapy Predictive Markers and Methods of Use 有权
标题翻译：预后和治疗预测标记和使用方法
公开(公告)号：US20090011439A1
公开(公告)日：2009-01-08
申请号：US12087964
申请日：2007-01-19
申请人： Ralph Weichselbaum , Bernard Roizman , Andy Minn , Nikolai Khodarev , Edwardine Labay
发明人： Ralph Weichselbaum , Bernard Roizman , Andy Minn , Nikolai Khodarev , Edwardine Labay
IPC分类号： G01N33/574
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , G01N33/57407 , G01N33/57484 , G01N2800/52
摘要： Disclosed is a set of genes differentially expressed in chemotherapy and radiation resistant tumors useful in predicting response to therapy and assessing risk of local-regional failure, survival and metastasis in cancer patients. Also disclosed are methods for characterizing tumors according to gene expression and kits for use in the methods of the invention.
摘要翻译：公开了一组在化学疗法和耐辐射肿瘤中差异表达的基因，可用于预测治疗反应和评估癌症患者局部局部衰竭，存活和转移的风险。还公开了根据基因表达表征肿瘤的方法和用于本发明方法的试剂盒。

5. 发明申请

US20080213258A1 Method of Predicting and Reducing Risk of Metastasis of Breast Cancer to Lung 有权
标题翻译：预测和降低乳腺癌转移肺部风险的方法
公开(公告)号：US20080213258A1
公开(公告)日：2008-09-04
申请号：US11813407
申请日：2006-01-05
申请人： Joan Massague , Gaorav P. Gupta , Andy Minn
发明人： Joan Massague , Gaorav P. Gupta , Andy Minn
IPC分类号： A61K39/395 , C12Q1/68 , C07H21/04 , A61K31/7052
CPC分类号： C12N15/1137 , C12N15/1136 , C12N2310/14 , C12Y114/99001
摘要： A signature for breast cancer tissue derived from a patient is established that is indicative of the virulence and risk of lung metastasis by determining the expression levels to define a sample signature, and comparing this sample signature to a reference signature. The reference signature defines a standard expression level for each gene and a significant change direction, i.e., either overexpressed or underexpressed. A sample signature that differs from the reference signature in the significant change direction for a predetermined number of the genes tested is indicative of a significant risk of lung metastasis. This determination is used to define appropriate treatment and monitoring options for the patient. Risk of metastasis to the lung can be reduced by treatment with a therapeutic combination that either (1) contains a first agent effective to inhibit epiregulin activity and a second agent effective to inhibit activity of a protein selected from the group consisting of MMP1, MMP2 and PTGS2, or (2) contains a therapeutic agent or combination of agents effective to inhibit activity MMP1, MMP2 and PTGS2. Agents that inhibit the CXCL1 pathway also can be used individually or in combination with these combinations.
摘要翻译：通过确定表达水平来确定样品标记，并将该样本标记与参考标记进行比较，建立了从患者衍生的乳腺癌组织的特征，其指示肺转移的毒力和风险。参考标记定义每个基因的标准表达水平和显着改变方向，即过表达或低表达。对于预定数量的所测试的基因，在显着改变方向上与参考标记不同的样本标记指示肺转移的显着风险。该确定用于为患者定义适当的治疗和监测选项。可以通过用（1）含有有效抑制去甲孕腺素活性的第一药剂和有效抑制选自MMP1，MMP2和 PTGS2或（2）含有有效抑制MMP1，MMP2和PTGS2活性的治疗剂或药剂组合。抑制CXCL1途径的药剂也可以单独使用或与这些组合组合使用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式